| ASAS40 | BASDAI 50 | ||||
---|---|---|---|---|---|---|
 | Response rate, n/N(%) | Unadjusted odds ratio | Pvalue | Response rate, n/N(%) | Unadjusted odds ratio | Pvalue |
 |  | (95% CI) |  |  | (95% CI) |  |
History of prior anti-TNF therapy | Â | Â | Â | Â | Â | Â |
   Prior ETN or IFX or both | 115/305 (37.7) | 0.41 (0.32 to 0.54) | < 0.001 | 128/314 (40.8) | 0.40 (0.31 to 0.53) | < 0.001 |
   No prior ETN/IFXa | 518/873 (59.3) |  |  | 561/890 (63.0) |  |  |
Prior TNF antagonist(s) | Â | Â | Â | Â | Â | Â |
   ETN only | 25/81 (30.9) | 0.93 (0.47 to 1.83) | 0.083 | 27/81 (33.3) | 0.98 (0.51 to 1.90) | 0.033 |
   IFX only | 66/150 (44.0) | 1.64 (0.91 to 2.93) |  | 75/156 (48.1) | 1.82 (1.03 to 3.20) |  |
   ETN and IFXa | 24/74 (32.4) |  |  | 26/77 (33.8) |  |  |
Reason for discontinuation of prior TNF antagonist | Â | Â | Â | Â | Â | Â |
   Loss of response | 46/108 (42.6) | 2.09 (1.05 to 4.14) | 0.108 | 47/112 (42.0) | 2.03 (1.03 to 4.03) | 0.059 |
   Intolerance | 20/52 (38.5) | 1.76 (0.79 to 3.91) |  | 25/54 (46.3) | 2.42 (1.11 to 5.30) |  |
   Lack of responsea | 16/61 (26.2) |  |  | 16/61 (26.2) |  |  |